RecruitingNCT05313308

A Survey of Midazolam in People With Status Epilepticus

BUCCOLAM OROMUCOSAL SOLUTION - Special Drug Use Surveillance


Sponsor

Clinigen K.K.

Enrollment

50 participants

Start Date

Jun 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

This study is a survey in Japan of midazolam oromucosal solution used to treat people with status epilepticus. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from midazolam oromucosal solution and to check if midazolam oromucosal solution improves symptoms of status epilepticus. During the study, participants with status epilepticus will take midazolam oromucosal solution according to their clinic's standard practice. The study doctors will check for side effects from midazolam for 6 months.


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Midazolam for people with epilepsy. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMidazolam

Midazolam oromucosal solution


Locations(1)

Clinigen selected site

Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05313308


Related Trials